The Oncologist, Vol. 5, Suppl 1, 3-10,
April 2000
© 2000 AlphaMed Press
VEGF Receptor Signaling in Tumor Angiogenesis
Gerald McMahon
SUGEN, Inc., South San Francisco, California, USA
Correspondence:
Gerald McMahon, Ph.D., Vice President, Drug Discovery, SUGEN, Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA. Telephone: 650-553-8774; Fax: 650-553-8307; e-mail: Jerry-mcmahon{at}SUGEN.com
The growth of human tumors and development of metastases depend on the de novo formation of blood vessels. The formation of new blood vessels is tightly regulated by specific growth factors that target receptor tyrosine kinases (RTKs). Vascular endothelial growth factor (VEGF) and the Flk-1/KDR RTK have been implicated as the key endothelial cell-specific factor signaling pathway required for pathological angiogenesis, including tumor neovascularization. Inhibition of the VEGF tyrosine kinase signaling pathway blocks new blood vessel formation in growing tumors, leading to stasis or regression of tumor growth. Advances in understanding the biology of angiogenesis have led to the development of several therapeutic modalities for the inhibition of the VEGF tyrosine kinase signaling pathway. A number of these modalities are under investigation in clinical studies to evaluate their potential to treat human cancers.
Key Words. Angiogenesis • Vascular endothelial growth factor (VEGF) • Tyrosine kinase receptors • Tyrosine kinase inhibitors
This article has been cited by other articles:

|
 |

|
 |
 
B. B. Aggarwal, M. E. Van Kuiken, L. H. Iyer, K. B. Harikumar, and B. Sung
Molecular Targets of Nutraceuticals Derived from Dietary Spices: Potential Role in Suppression of Inflammation and Tumorigenesis
Exp Biol Med,
August 1, 2009;
234(8):
825 - 849.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. H. Jung, S. H. Lee, E.-M. Ahn, and Y. M. Lee
Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway
Carcinogenesis,
April 1, 2009;
30(4):
655 - 661.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Jain, G. Chakraborty, R. Raja, S. Kale, and G. C. Kundu
Prostaglandin E2 Regulates Tumor Angiogenesis in Prostate Cancer
Cancer Res.,
October 1, 2008;
68(19):
7750 - 7759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ning, J. A. Nemeth, R. L. Hanson, K. Forsythe, and S. J. Knox
Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo
Mol. Cancer Ther.,
June 1, 2008;
7(6):
1569 - 1578.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Rodriguez-Porcel, W. Cai, O. Gheysens, J. K. Willmann, K. Chen, H. Wang, I. Y. Chen, L. He, J. C. Wu, Z.-b. Li, et al.
Imaging of VEGF Receptor in a Rat Myocardial Infarction Model Using PET
J. Nucl. Med.,
April 1, 2008;
49(4):
667 - 673.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-W. Lee, S. G. Kim, H.-P. Kim, E. Kwon, J. You, H.-J. Choi, J.-H. Park, B.-C. Kang, S.-A. Im, T.-Y. Kim, et al.
Enzastaurin, a Protein Kinase C{beta} Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells
Cancer Res.,
March 15, 2008;
68(6):
1916 - 1926.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Callaghan, E. Crowley, S. Potter, and I. D. Kerr
P-glycoprotein: So Many Ways to Turn It On
J. Clin. Pharmacol.,
March 1, 2008;
48(3):
365 - 378.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Morschhauser, J. F. Seymour, H. C. Kluin-Nelemans, A. Grigg, M. Wolf, M. Pfreundschuh, H. Tilly, J. Raemaekers, M. B. van 't Veer, N. Milpied, et al.
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
Ann. Onc.,
February 1, 2008;
19(2):
247 - 253.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Chakraborty, S. Jain, and G. C. Kundu
Osteopontin Promotes Vascular Endothelial Growth Factor Dependent Breast Tumor Growth and Angiogenesis via Autocrine and Paracrine Mechanisms
Cancer Res.,
January 1, 2008;
68(1):
152 - 161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Mohamedali, A. T. Poblenz, C. R. Sikes, N. M. Navone, P. E. Thorpe, B. G. Darnay, and M. G. Rosenblum
Inhibition of Prostate Tumor Growth and Bone Remodeling by the Vascular Targeting Agent VEGF121/rGel.
Cancer Res.,
November 15, 2006;
66(22):
10919 - 10928.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Carducci, L. Musib, M. S. Kies, R. Pili, M. Truong, J. R. Brahmer, P. Cole, R. Sullivan, J. Riddle, J. Schmidt, et al.
Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer
J. Clin. Oncol.,
September 1, 2006;
24(25):
4092 - 4099.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Su, Q. Zheng, M. M. Vaughan, Y. Bu, and I. H. Gelman
SSeCKS Metastasis-Suppressing Activity in MatLyLu Prostate Cancer Cells Correlates with Vascular Endothelial Growth Factor Inhibition
Cancer Res.,
June 1, 2006;
66(11):
5599 - 5607.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. W. Siemann, M. C. Bibby, G. G. Dark, A. P. Dicker, F. A.L.M. Eskens, M. R. Horsman, D. Marme, and P. M. LoRusso
Differentiation and Definition of Vascular-Targeted Therapies
Clin. Cancer Res.,
January 15, 2005;
11(2):
416 - 420.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Nakamura, A. Yamamoto, M. Kamishohara, K. Takahashi, E. Taguchi, T. Miura, K. Kubo, M. Shibuya, and T. Isoe
KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth
Mol. Cancer Ther.,
December 1, 2004;
3(12):
1639 - 1649.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-K. Min, K.-Y. Han, E.-C. Kim, Y.-M. Kim, S.-W. Lee, O.-H. Kim, K.-W. Kim, Y. S. Gho, and Y.-G. Kwon
Capsaicin Inhibits in Vitro and in Vivo Angiogenesis
Cancer Res.,
January 15, 2004;
64(2):
644 - 651.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Moshinsky, L. Ruslim, R. A. Blake, and F. Tang
A Widely Applicable, High-Throughput TR-FRET Assay for the Measurement of Kinase Autophosphorylation: VEGFR-2 as a Prototype
J Biomol Screen,
August 1, 2003;
8(4):
447 - 452.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. K. Nuttall, C. J. Pennington, J. Taplin, A. Wheal, V. W. Yong, P. A. Forsyth, and D. R. Edwards
Elevated Membrane-Type Matrix Metalloproteinases in Gliomas Revealed by Profiling Proteases and Inhibitors in Human Cancer Cells
Mol. Cancer Res.,
March 1, 2003;
1(5):
333 - 345.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li and F. H. Sarkar
Gene Expression Profiles of Genistein-Treated PC3 Prostate Cancer Cells
J. Nutr.,
December 1, 2002;
132(12):
3623 - 3631.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-M. Kim, S. Hwang, Y.-M. Kim, B.-J. Pyun, T.-Y. Kim, S.-T. Lee, Y. S. Gho, and Y.-G. Kwon
Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1
J. Biol. Chem.,
July 26, 2002;
277(31):
27872 - 27879.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Griffin, B. W. Williams, R. Wild, J. M. Cherrington, H. Park, and C. W. Song
Simultaneous Inhibition of the Receptor Kinase Activity of Vascular Endothelial, Fibroblast, and Platelet-derived Growth Factors Suppresses Tumor Growth and Enhances Tumor Radiation Response
Cancer Res.,
March 1, 2002;
62(6):
1702 - 1706.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Rao, B. Puschner, and T. A. Prolla
Gene Expression Profiling of Low Selenium Status in the Mouse Intestine: Transcriptional Activation of Genes Linked to DNA Damage, Cell Cycle Control and Oxidative Stress
J. Nutr.,
December 1, 2001;
131(12):
3175 - 3181.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. F. List
Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies
Oncologist,
October 1, 2001;
6(2008):
24 - 31.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. A. Teicher, K. Menon, E. Alvarez, E. Galbreath, C. Shih, and M. Faul
Antiangiogenic and Antitumor Effects of a Protein Kinase C{beta} Inhibitor in Human T98G Glioblastoma Multiforme Xenografts
Clin. Cancer Res.,
March 1, 2001;
7(3):
634 - 640.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
H.-P. Gerber, J. Kowalski, D. Sherman, D. A. Eberhard, and N. Ferrara
Complete Inhibition of Rhabdomyosarcoma Xenograft Growth and Neovascularization Requires Blockade of Both Tumor and Host Vascular Endothelial Growth
Cancer Res.,
November 1, 2000;
60(22):
6253 - 6258.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by AlphaMed Press.
|
|